New developments in the treatment of postmenopausal breast cancer

This publication has 31 references indexed in Scilit:

• Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
  The Lancet, 2005
• Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant
  Breast Cancer Research and Treatment, 2005
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
  The Lancet, 2005
• American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004
  Journal of Clinical Oncology, 2005
• A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
  New England Journal of Medicine, 2004
• A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
  New England Journal of Medicine, 2003
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer
  Cancer, 2003
• Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation
  Journal of Biological Chemistry, 2003
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
  The Lancet, 2002
• Similarities and distinctions in the mode of action of different classes of antioestrogens.
  Endocrine-Related Cancer, 2000